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Background: We report a case of severe bilateral panuveitis during melanoma therapy with a combination of
Dabrafenib, a B-raf (BRAF) inhibitor, and Trametinib, a mitogen/extracellular signal-regulated kinase (MEK) inhibitor.
Both of these drugs are effectors in the mitogen-activated protein kinase (MAPK) pathway, which plays an important
role in the physiopathology of melanoma. Dabrafenib and Trametinib have shown improved survival of patients with
metastatic melanoma but they have also been associated with the development of uveitis.
Findings: Our patient was a 55-year-old woman with metastatic melanoma who presented with sudden onset of
bilateral painless visual loss. She had been treated with Dabrafenib and Trametinib. Trametinib was discontinued
at the onset of symptoms but there was no improvement. Ophthalmological examination revealed severe bilateral
non-granulomatous panuveitis, with choroidal thickening, chorio-retinal folds, and multiple serous retinal detachments
(SRDs). Topical corticosteroid treatment was initiated, and Dabrafenib was discontinued. A good response was obtained
with a recovery of visual acuity of 20/25 on both eyes and an almost complete resolution of the SRDs.
Conclusions: This case highly suggests that MAPK pathway inhibition can lead to severe uveitis. Dabrafenib and
Trametinib could have both played a role in inducing the disease. Further studies are needed to evaluate the
possible role of the combination of these drugs in inducing uveitis and SRD.
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Introduction
Medications are recognized as an increasingly common
cause for uveitis [1]. In this article, we report a case of
severe bilateral panuveitis during melanoma therapy with
a combination of Dabrafenib, a B-raf (BRAF) inhibitor,
and Trametinib, a mitogen/extracellular signal-regulated
kinase (MEK) inhibitor. Progress in pharmacological re-
search has led to the development of novel, more effective,
and more specific drugs for melanoma. Some of them
could be responsible for side effects, such as uveitis.
The mitogen-activated protein kinase (MAPK) pathway
plays a key role in the development of melanoma. Mu-
tations in effectors of this pathway, such as BRAF and
MEK, lead to increased survival and proliferation of
melanoma cells [2]. Targeting these molecules has led
to the development of promising drugs. Vemurafenib* Correspondence: dafina.draganova@gmail.com
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medium, provided the original work is properlyand Dabrafenib are BRAFV600 inhibitors licensed for the
treatment of adults presenting the BRAFV600E mutation
and nonresectable or metastatic melanoma [2]. Trametinib
is a MEK inhibitor approved for the same indication, as
well as for a combination with Dabrafenib [2]. A combin-
ation of these molecules has shown an improved response
rate in patients with metastatic melanoma [2]. A recent
publication by Guedj et al. [3] described a series of seven
patients who developed Vemurafenib-induced bilateral
non-granulomatous anterior uveitis. Vemurafenib-induced
uveitis was also reported by Choe et al. [4]. Another article
describes a severe bilateral vitritis and optic disk leakage oc-
curring 3 weeks after starting combined treatment with
Dabrafenib and Trametinib, with resolution 6 weeks after
the cessation of both drugs [5]. The large multicentre trials
for the approval of Dabrafenib report the occurrence of 1 %
of uveitis of unspecified severity [6]. The occurrence of
serous retinal detachments (SRDs), once associated
with moderate anterior uveitis, has been reported in
Trametinib therapy [7,8]. Uveitis was resolved on topical
therapy without the cessation of Trametinib.s article distributed under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any
credited.
Fig. 1 Color fundus photographs. a, b Upper panel: at presentation, fundus details are masked by anterior fibrin and vitreous haze resulting from
severe inflammation, but optic disk hyperhemia can be detected on the left side. The superonasal round yellow area on the left side is an artifact.
c, d Lower panel: 1 month after drug arrest, resolution of the inflammation allows normal fundus visualization including normal optic disks
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Our patient was a 55-year-old woman with metastatic
cutaneous melanoma of unknown primary site who
presented in June 2014 with sudden onset of bilateral
painless visual loss. She had been treated with Dabrafenib
150 mg twice daily since November 2013 and Trametinib
2 mg once daily was added in April 2014. Trametinib wasFig. 2 HR-OCT. a, b Upper panel: at presentation: multiple serous retinal detac
folds are observed. c, d Lower panel: 1 month after drug arrest, there is an alm
chorio-retinal foldsdiscontinued at the onset of symptoms by her oncologist,
but there was no improvement after 10 days. The patient’s
visual acuity was hand movements OD and counting
fingers OS. Slit lamp examination revealed the following
symmetric findings: no keratic precipitates, anterior cham-
ber cells 2+ with fibrin, synechiae on 360°, and vitritis.
Fundus details on both eyes were masked by anteriorhments, loss of normal choroidal vascular architecture, and chorio-retinal
ost complete resolution of the serous retinal detachments and of the
Draganova et al. Journal of Ophthalmic Inflammation and Infection  (2015) 5:17 Page 3 of 3fibrin and vitreous haze resulting from severe inflamma-
tion, but optic disk hyperhemia could be detected on
the left side and some chorio-retinal folds were visible
on both eyes (Fig. 1, upper panel). Fluoangiography
showed bilateral hot disks. However, due to the inten-
sity of the inflammation, it was of insufficient quality to
reveal other details. HR-OCT showed thickening and
loss of normal choroidal vascular architecture, presence
of chorio-retinal folds and multiple SRDs on both eyes
(Fig. 2, upper panel). Uveitis work-up including blood
work-up, chest X-ray, and a tuberculin skin test was
negative. Topical corticosteroid treatment (one drop
per hour) was initiated, and Dabrafenib was discontinued
in agreement with the oncologist. A good response was
obtained with a recovery of a visual acuity of 20/25 on
both eyes, no detectable inflammation, and an almost
complete resolution of the SRDs 1 month later (Figs. 1
and 2, lower panel). Further follow-up was impossible be-
cause the patient sadly passed away in September 2014.
Discussion
To the best of our knowledge, this case report is the first
to describe the simultaneous occurrence of severe non-
granulomatous uveitis, SRDs, and chorio-retinal folds
during combined Dabrafenib and Trametinib treatment.
Even though the most common causes of uveitis are
inflammatory or infectious disorders, medication side
effects should always be considered in the differential
diagnosis. There are several drugs for which the clinical
experience is sufficient to establish a “definite,” “probable,”
or “possible” association with uveitis using an algorithm
proposed by Naranjo and associates [9]. Other more re-
cent drugs, such as MAPK pathway inhibitors, have been
described as inductors of uveitis in several independent
publications. Currently, the best-documented cases are
those presented in the series of Guedj et al. and Choe et al.,
concerning Vemurafenib [3]. Our case strongly suggests
that BRAF inhibitor-induced uveitis is not restricted to
Vemurafenib but can also occur with Dabrafenib. Our
patient also received Trametinib, a MEK inhibitor that
could have played a role in inducing the disease. Even
though interruption of this medication did not result in
clinical improvement, we cannot be certain that Dabrafenib
alone could have caused the uveitis. In conclusion, it is
probable that MAPK pathway inhibition can lead to severe
uveitis. Further studies are needed to identify the patients
who are at risk of developing this side effect, as well as to
explore the possible role of the combination of several
MAPK inhibitors in the induction of uveitis and SRD.Consent
Approval for the publication of this report and any ac-
companying images was obtained from the ethicscommittee of Jules Bordet Institute since the patient
passed away before the request of informed consent.
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